1-cyano-1-methyl-ethylphenylcarbonate | 130312-20-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-cyano-1-methyl-ethylphenylcarbonate
• 英文别名: 2-cyanopropan-2-yl phenyl carbonate
• CAS: 130312-20-8
• 化学式: C₁₁H₁₁NO₃
• 分子量: 205.213
• InChiKey: IESSWZDMKFMYRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-4-((2-(2-methylpiperazin-1-yl)pyrimidin-5-yloxy)methyl)nicotinonitrile 、 1-cyano-1-methyl-ethylphenylcarbonate 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 18.0h， 以16%的产率得到1-cyano-1-methylethyl (3R)-4-{5-[(3-cyanopyridin-4-yl)methoxy]pyrimidin-2-yl}-3-methylpiperazine-1-carboxylate
  参考文献：
  名称：

  Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation

  摘要：

  G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward discovering agonists of GPR119, we herein describe optimization of an initial lead compound, 2, into a development candidate, 42. A key challenge in this program of work was the insolubility of the lead compound. Small-molecule crystallography was utilized to understand the intermolecular interactions in the solid state and resulted in a switch from an aryl sulphone to a 3-cyanopyridyl motif. The compound was shown to be effective in wild-type but not knockout animals, confirming that the biological effects were due to GPR119 agonism.

  DOI：

  10.1021/jm300310c
• 作为产物：
  描述：

  丙酮氰醇 、 氯甲酸苯酯 在 吡啶 作用下， 反应 0.5h， 以100%的产率得到1-cyano-1-methyl-ethylphenylcarbonate
  参考文献：
  名称：

  三唑并噻二氮杂卓衍生物作为血小板活化因子拮抗剂的结构活性研究。

  摘要：

  合成了一系列三唑并二氮杂并评估其抗血小板活化因子（PAF）活性。关于该系列的结构-活性关系（SAR）研究表明，将甲基引入噻二氮杂卓核的8位可导致作用时间延长。甲基的引入产生不对称中心，并且由此形成的对映异构体用光学拆分柱分离。在体外测定系统中，（+）异构体显示出比（-）异构体有效的抗PAF活性高50-200倍。比较毒理学和药代动力学后，（+）-6-（2-氯苯基）-3-环丙烷羰基-8,11-二甲基-2,3,4,5-四氢-8H-吡啶基[4'，3'：4 ，5] thieno [3,2-f] [1,2,4]三唑并[4,3-a] [1,4]二氮杂（（35（+）-异构体，

  DOI：

  10.1248/cpb.39.3215

文献信息

• Therapeutic Agents 812
  申请人：Birch Alan Martin

  公开号：US20110065706A1

  公开（公告）日：2011-03-17

  A compound of formula I or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as GPR119 modulators, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus, and pharmaceutical compositions containing them.

  公式I的化合物或其药用可接受的盐，制备这类化合物的方法，它们作为GPR119调节剂的用途，它们的治疗用途的方法，特别是在肥胖和糖尿病的治疗中，以及含有它们的药物组合物。
• 1,4-diazepine derivative and its pharmaceutical use
  申请人：Eisai Co., Ltd.

  公开号：EP0367110A1

  公开（公告）日：1990-05-09

  A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl. X is -OCO-, -NHCO-, -CO- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

  本发明公开了一种下式的三唑并-1,4-二氮杂卓化合物及其药理上可接受的盐，该化合物在医药领域，特别是过敏性疾病领域非常有用。 其中 R1 和 R2 是氢或烷基，R3 是氢或卤素，R4 是氢或烷基。X 是-OCO-、-NHCO-、-CO-或其它，Y 是环烷基、环烷基烷基、炔基或其它。
• Thieno 3.2-f 1,2,4 triazolo 4,3-a 1,4 -diazepine derivatives as PAF antagonists
  申请人：Eisai Co., Ltd.

  公开号：EP0606103A1

  公开（公告）日：1994-07-13

  A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is -OCO-, -NHCO-, -CO- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

  本发明公开了一种下式的三唑并-1,4-二氮杂卓化合物及其药理上可接受的盐，该化合物在制药领域，特别是过敏性疾病领域非常有用。 其中 R1 和 R2 是氢或烷基，R3 是氢或卤素，R4 是氢或烷基，X 是 -OCO-、-NHCO-、-CO- 或其它，Y 是环烷基、环烷基烷基、炔基或其它。
• Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives as PAF antagonists
  申请人：Eisai Co., Ltd.

  公开号：EP0677524A1

  公开（公告）日：1995-10-18

  A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is -OCO-, -NHCO-, -CO- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others. with the proviso that when R₁ is hydrogen then R₂ cannot be methyl.

  本发明公开了一种下式的三唑并-1,4-二氮杂卓化合物及其药理上可接受的盐，该化合物在制药领域，特别是过敏性疾病领域非常有用。 其中 R1 和 R2 是氢或烷基，R3 是氢或卤素，R4 是氢或烷基，X 是 -OCO-、-NHCO-、-CO- 或其它，Y 是环烷基、环烷基烷基、炔基或其它。 但当 R₁ 为氢时，R₂ 不能为甲基。
• Thieno[3,2-f](1,2,4-triazolo)[4,3-a]1,4-diazepine derivatives as PAF antagonists
  申请人：Eisai Co., Ltd.

  公开号：EP0677524B1

  公开（公告）日：2002-02-13